Sleep disturbance and fatigue in mild relapsing remitting multiple sclerosis patients on chronic immunomodulant therapy: An actigraphic study

Multiple Sclerosis

Volumn 16, Issue 2, 2010, Pages 238-247

  Mendozzi, Laura ^a   Tronci, Federica ^a   Garegnani, Massimo ^b   Pugnetti, Luigi ^b  

^a Multiple Sclerosis Centre   (Italy)

^b IRCCS FONDAZIONE DON CARLO GNOCCHI   (Italy)

Author keywords

Actigraphy; Chronic therapy; Fatigue; Glatiramer acetate; Interferon ; Multiple sclerosis; Side effects; Sleep

Indexed keywords

BETA INTERFERON; BETA1A INTERFERON; GLATIRAMER; IMMUNOMODULATING AGENT; INTERFERON BETA SERINE;

ACTIMETRY; ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISABILITY; DISEASE DURATION; DISEASE SEVERITY; FATIGUE; HOME; HUMAN; MEDICAL ASSESSMENT; MULTIPLE SCLEROSIS; PATIENT MONITORING; QUESTIONNAIRE; RATING SCALE; SLEEP DISORDER; TREATMENT DURATION; TREATMENT PLANNING;

ACTIGRAPHY; ADULT; DISABILITY EVALUATION; DRUG ADMINISTRATION SCHEDULE; FATIGUE; HUMANS; IMMUNOLOGIC FACTORS; INTERFERON-BETA; MIDDLE AGED; MOTOR ACTIVITY; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; PEPTIDES; PREDICTIVE VALUE OF TESTS; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX; SLEEP; SLEEP DISORDERS; TIME FACTORS; TREATMENT OUTCOME;

EID: 76449087607     PISSN: 13524585     EISSN: None     Source Type: Journal    
DOI: 10.1177/1352458509354551     Document Type: Article

References (36)

1. Merlino G., Fratticci L., Lenchig C., et al. Prevalence of poor sleep among patients with multiple sclerosis: An independent predictor of mental and physical status. Sleep Med 2009 ; 10: 26-34.
2. Attarian H. Importance of sleep in the quality of life of multiple sclerosis patients: A long under-recognized issue. Sleep Med 2009 ; 10: 7-8.
3. Bamer AM, Johnson KL, Amtmann D., Kraft GH Prevalence of sleep problems in individuals with multiple sclerosis. Mult Scler 2008 ; 14: 1127-1130.
4. Manconi M., Rocca MA, Ferini-Strambi L., et al. Restless legs syndrome is a common finding in multiple sclerosis and correlates with cervical cord damage. Mult Scler 2008 ; 14: 86-93.
5. Fleming WE, Pollak CP Sleep disorders in multiple sclerosis. Semin Neurol 2005 ; 25: 64-68.
6. Spath-Schwalbe E., Lange T., Perras B., Fehm HL, Born J. Interferon-α acutely impairs sleep in healthy humans. Cytokine 2000 ; 12: 518-521.
7. Kümpfel T., Schwan M., PollmáCurrency signcher T., et al. Time of interferon-beta 1a injection and duration of treatment affect clinical side effects and acute changes of plasma hormone and cytokine levels in multiple sclerosis patients. Mult Scler 2007 ; 13: 1138-1145.
8. Stanton BR, Barnes F., Silber E. Sleep and fatigue in multiple sclerosis. Mult Scler 2006 ; 12: 481-486.
9. Spirin NN, Kasatkin DS The influences of cytokines as a possible substrate for the psychological effects of immunomodulation therapy in multiple sclerosis. Neurosci Behav Physiol 2009 ; 39: 25-30.
10. Ferini-Strambi L., Filippi M., Martinelli V., et al. Nocturnal sleep study in multiple sclerosis: correlations with clinical and brain magnetic resonance imaging findings. J Neurol Sci 1994 ; 125: 194-197.
11. Kaynak H., AltintaÅ A., Kaynak D., et al. Fatigue and sleep disturbance in multiple sclerosis. Eur J Neurol 2006 ; 13: 1333-1339.
12. Berger AM, Wielgus KK, Young-McCaughan S., Fischer P., Farr L., Lee KA Methodological challenges when using actigraphy in research. J Pain Symptom Manage 2008 ; 36: 191-199.
13. Landis CA, Frey CA, Lentz MJ, Rothermel J., Buchwald D., Shaver JLF Self-reported sleep quality and fatigue correlates with actigraphy in midlife women with fibromyalgia. Nurs Res 2003 ; 52: 140-147.
14. Attarian HP, Brown KM, Duntley SP, Carter JD, Cross AH The relationship of sleep disturbances and fatigue in multiple sclerosis. Arch Neurol 2004 ; 61: 525-528.
15. McDonald WI, Compston A., Edan G., et al. Recommended diagnostic criteria for multiple sclerosis: guidelines from the International Panel on the diagnosis of multiple sclerosis. Ann Neurol 2001 ; 50: 121-127.
16. Krupp LB, LaRocca NG, Muir-Nash J., Steinberg AD The fatigue severity scale. Application to patients with multiple sclerosis and systemic lupus erythematosus. Arch Neurol 1989 ; 46: 1121-1123.
17. Fischer JS, LaRocca NG, Miller DM, Ritvo PG, Andrews H., Paty D. Recent developments in the assessment of quality of life in multiple sclerosis (MS). Mult Scler 1999 ; 5: 251-259.
18. Johns MW A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991 ; 14: 540-545.
19. Hays RD, Stewart AL Sleep measures. In: Stewart AL, Ware JE (eds) Measuring functioning and well being: the medical outcome study approach. Durham, NC: Duke University Press, 1992, p. 235-259.
20. Hays RD, Martin SA, Sesti AM, Spritzer KL Psychometric properties of the Medical Outcomes Study Sleep measure. Sleep Med 2005 ; 6: 41-44.
21. Sadosky A., Dukes E., Evans C. Reliability of a I-week recall period for the Medical Outcomes Study Sleep Scale (MOS-SS) in patient with fibromyalgia. Health Qual Life Outcomes 2009 ; 7: 12-17.
22. Spritzer KL, Hays RD MOS sleep scale: a manual for use and scoring, Version 1.0. Los Angeles, CA, 2003.
23. Sadeh A., Sharkey KM, Carskadon MA Activity-based sleep-wake identification: an empirical test of methodological issues. Sleep 1994 ; 17: 201-207.
24. Taphoorn MJB, van Someren E., Snoek FJ, et al. Fatigue, sleep disturbances and circadian rhythm in multiple sclerosis. J Neurol 1993 ; 240: 446-448.
25. Vetrugno R., Stecchi S., Scandellari C., et al. Sleep-wake and body core temperature rhythms in multiple sclerosis with fatigue. Clin Neurophysiol 2007 ; 118: 228-234.
26. Leuschen MP, Filipi M., Healey K. A randomized open label study of pain medications (naproxen, acetaminophen and ibuprofen) for controlling side effects during initiation of IFNβ Ia therapy and during its ongoing use for relapsing-remitting multiple sclerosis. Mult Scler 2004 ; 10: 636-642.
27. Huber S., Spycher M., Lechner-Scott J., et al. Multiple Sclerosis: therapy with recombinant beta-1b interferon: initial results with 30 multiple sclerosis patient in north-west Switzerland. Schweiz Med Wochenschr 1996 ; 126: 1475-1481.
28. Brochet B. Long-term effects of glatiramer acetate in multiple sclerosis. Rev Neurol 2008 ; 164: 917-926.
29. Johnson KP, Brooks BR, Ford CC, et al. Sustained clinical benefits of glatiramer acetate in relapsing multiple sclerosis patients observed for 6 years. Copolymer 1 Multiple Sclerosis Study Group. Mult Scler 2000 ; 6: 255-266.
30. Ziemssen T., Hoffman J., Apfel R., Kern S. Effects of glatiramer acetate on fatigue and days of absence from work in first-time treated relapsing-remitting multiple sclerosis. Health Qual Life Outcomes 2008 ; 6: 67-72.
31. Viala-Danten M., Matin S., Guillemin I., Hays RD Evaluation of the reliability and validity of the Medical Outcomes Study Sleep Scale in patient with painful diabetic peripheral neuropathy during an international clinical trial. Health Qual Life Outcomes 2008 ; 6: 113-124.
32. Cappelleri JC, Bushmaking AG, McDermott AM, et al. Measurement properties of the Medical Outcomes Study Sleep Scale in patients with fibromyalgia. Sleep Med 2009 ; 10: 766-770.
33. Ferini-Stambi L., Aarskog D., Pertinen M., et al. Effect of pramipexole on RLS symptoms and sleep: A randomize, double blind, placebo-controlled trial. Sleep Med 2008 ; 9: 874-881.
34. Sepulcre J., Masdeu JC, Goá±i J., et al. Fatigue in multiple sclerosis is associated with the disruption of frontal and parietal pathways. Mult Scler 2009 ; 15: 337-344.
35. Gottberg K., Gardulf A., Fredrikson S. Interferon-beta treatment for patients with multiple sclerosis: the patients perceptions of the side-effects. Mult Scler 2000 ; 6: 349-354.
36. Kos D., Kerckhofs E., Nagels G., Dhooghe MB, Ilsbroukx S. Origin of fatigue in multiple sclerosis: review of the literature. Neurorehabil Neural Repair 2008 ; 22: 91-100.